News Release

Change of Distributorship to “Glucagon G Novo 1 mg”

August 31, 2022

EA Pharma Co., Ltd.
Novo Nordisk Pharma Ltd.

EA Pharma Co., Ltd. (Representative Director, President and CEO, Hidenori Yabune; Headquarters, Chuo-ku, Tokyo, Japan, “EA Pharma”) and Novo Nordisk Pharma Ltd. (President and Representative Director, Ole Mølskov Bech; Headquarters, Chiyoda-ku, Tokyo, Japan, “Novo Nordisk Pharma”) announced today that the distributorship to “Glucagon G Novo 1 mg” (“the Product”) is to be transferred from EA Pharma to Novo Nordisk Pharma as of December 1st, 2022.

The Product is mainly used in preparation for gastrointestinal (“GI”) tract radiography or endoscopy for the purpose of suppressing peristaltic movement of the GI tract to facilitate the examination. The Product is also used for emergency treatment of hypoglycemia, tests for growth hormone secretory status, tests for glycogen storage disease of liver or preparation for upper GI endoscopy.

Novo Nordisk Pharma holds the manufacture and marketing authorization of the Product. Novo Nordisk Pharma has manufactured, and EA Pharma has distributed the Product up to the present in Japan. Upon expiration of the agreement between the two companies, distribution by EA Pharma terminates, and Novo Nordisk Pharma undertakes manufacture through marketing of the Product in the future.

As of December 1st, 2022 and later, Novo Nordisk Pharma will be the information provider and distributor of the Product. The labels on the product package may include former indications due to consumption of stocks in logistics for the time being until completion of replacement by new ones.

EA Pharma and Novo Nordisk Pharma are committed to smooth change of the distributorship.

EA Pharma Co., Ltd.

Corporate Communications Dept.

TEL： +81(0)80-4176-5206
Novo Nordisk Pharma Ltd.

Communications

TEL： +81(0)3-6266-1303

《More Information》

1. About Glucagon

Glucagon is a pancreatic hormone which has the functions of raising blood sugar and suppressing movement of the GI tract. Glucagon is often used in a preparatory procedure for gastrointestinal examination by radiography or endoscopy or endoscopic therapy for its function of suppressing the peristatic movement of the GI tract. Glucagon is also used for treatment of hypoglycemia, stimulation test and screening of hepatic glycogenosis, which is a condition that excessive glycogen or glycogen of abnormal structure accumulates in the liver, muscles or other organs.

2. About EA Pharma Co., Ltd.

EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the gastrointestinal business unit with more than 60 year’s history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business core. EA Pharma is a gastrointestinal specialty pharma with a full value chain covering R&D, logistics and sales & marketing.

For more information on EA Pharma Co., Ltd., please see https://www.eapharma.co.jp/en/

3. About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk Pharma Ltd. in Japan was established in 1980. Please see www.novonordisk.co.jp for more details.

PDF(123KB)

Back